Cost-effectiveness Analysis of Serplulimab Combined with Chemotherapy for the First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer
10.3870/j.issn.1004-0781.2025.04.025
- VernacularTitle:斯鲁利单抗联合化疗一线治疗晚期鳞状非小细胞肺癌的成本-效果分析
- Author:
Lei XU
1
;
Hao WANG
;
Weihong GE
Author Information
1. 南京中医药大学鼓楼临床医学院药学部,南京 210008
- Publication Type:Journal Article
- Keywords:
Serplulimab;
Squamous non-small cell lung cancer;
Partitioned survival model;
Cost-effectiveness analysis
- From:
Herald of Medicine
2025;44(4):662-668
- CountryChina
- Language:Chinese
-
Abstract:
Objective From the perspective of China's health service system,to evaluate the economy of the first-line treatment of advanced squamous non-small cell lung cancer with serplulimab combined with chemotherapy.Methods A three-state partitioned survival model was constructed,and the cost-effectiveness method was used to evaluate the economy of serplulimab combined chemotherapy in the first-line treatment of advanced squamous non-small cell lung cancer.The clinical data were collected from the ASTRUM-004 trial.The quality adjusted life years(QALYs)were used as the output index and the incremental cost-effectiveness ratio(ICER)was calculated.The stability of the model was verified by sensitivity analysis,and the situation analysis was carried out for the decrease of the price of serplulimab.Results The results of basic analysis showed that the cost of the combination group increased by 1 951 442 yuan compared with the placebo combination chemotherapy group,and the ICER was 2 498 816.54 yuan/QALY.Single factor sensitivity analysis showed that PFS state utility value,body weight,and serplulimab price had a greater impact on ICER.Probabilistic sensitivity analysis showed that the basic analysis results are robust.The results of the scenario analysis showed that when the price of serplulimab was reduced by 20％and 80％,it was not economical.Conclusions From the perspective of the China's health service system,currently,the combination therapy of serplulimab with chemotherapy is not cost-effective in the first-line treatment of advanced squamous cell lung cancer compared to placebo combination therapy.
